Patients with gastric cancer often present with poor performance status, limiting both quality of life but also treatment options as they are often excluded from clinical trials. Here, the authors report a phase II trial investigating anlotinib (multi-TKI) plus toripalimab (anti-PD-L1 monoclonal antibody) in treatment-naïve advanced gastric cancer patients with performance status 2.
- Ke Liu
- Bao-Dong Qin
- Yuan-Sheng Zang
